BlackRock (ALDX holder) discloses 1.7% Aldeyra Therapeutics stake in amended 13G

Rhea-AI Filing Summary

BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership in Aldeyra Therapeutics, Inc. (ALDX) common stock. BlackRock reports beneficial ownership of 1,045,764 shares of common stock, representing 1.7% of the class. All of these shares are reported with sole voting power and sole dispositive power, with no shared voting or dispositive power.

The filing notes that the reported position reflects securities beneficially owned, or deemed to be beneficially owned, by certain business units of BlackRock and its subsidiaries and affiliates, excluding other disaggregated units. BlackRock also states that various persons have rights to dividends or sale proceeds related to these shares, but no such person holds more than five percent of Aldeyra’s outstanding common stock.

Key Figures

Beneficially owned shares: 1,045,764 shares Percent of class: 1.7% Sole voting power: 1,045,764 shares +3 more

6 metrics

Beneficially owned shares 1,045,764 shares Common stock of Aldeyra Therapeutics reported by BlackRock

Percent of class 1.7% Portion of Aldeyra Therapeutics common stock class held by BlackRock

Sole voting power 1,045,764 shares Shares over which BlackRock has sole power to vote or direct the vote

Shared voting power 0 shares Shares over which BlackRock has shared power to vote

Sole dispositive power 1,045,764 shares Shares over which BlackRock has sole power to dispose or direct disposition

Shared dispositive power 0 shares Shares over which BlackRock has shared power to dispose

Key Terms

beneficially owned, Sole Voting Power, dispositive power, parent holding company or control person, +1 more

5 terms

beneficially owned financial

"this reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power financial

"5 | Sole Voting Power 1,045,764.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

dispositive power financial

"Sole Dispositive Power 1,045,764.00 8 | Shared Dispositive Power 0.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

parent holding company or control person financial

"Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person"

Power of Attorney regulatory

"Exhibit 24: Power of Attorney Exhibit 99: Item 7"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/27/2026 - 04:26 PM Accepted by SEC EDGAR 07/27/2026 - 04:25 PM Learn about SEC filing dates

FAQ

What percentage of Aldeyra Therapeutics (ALDX) does BlackRock currently report owning?

BlackRock reports beneficial ownership of 1.7% of Aldeyra Therapeutics’ common stock. This corresponds to 1,045,764 shares with sole voting and dispositive power, as disclosed in the amended Schedule 13G filing.

How many ALDX shares does BlackRock report as beneficially owned?

BlackRock reports beneficial ownership of 1,045,764 Aldeyra Therapeutics common shares. These shares are all reported with sole voting and sole dispositive power, and no shares are reported as shared voting or shared dispositive power.

Does BlackRock share voting or dispositive power over its ALDX holdings?

BlackRock indicates it has sole voting power and sole dispositive power over 1,045,764 shares of Aldeyra Therapeutics. The filing reports zero shares with shared voting power and zero shares with shared dispositive power.

Why is BlackRock’s Aldeyra Therapeutics (ALDX) holding reported on Schedule 13G/A?

The position is reported on an amended Schedule 13G because BlackRock is a large institutional investor filing as a parent holding company. The filing reflects securities beneficially owned by certain BlackRock business units, in line with SEC Release No. 34-39538.

Do any other investors have more than 5% interest through BlackRock’s ALDX holdings?

The filing states that various persons may receive dividends or sale proceeds from Aldeyra shares held by BlackRock, but no one person has an interest in more than five percent of Aldeyra’s total outstanding common shares.

Who signed the Schedule 13G/A filing for Aldeyra Therapeutics (ALDX) on behalf of BlackRock?

The Schedule 13G/A was signed by Spencer Fleming, a Managing Director at BlackRock, Inc. The filing also references Exhibit 24 as a Power of Attorney authorizing the signatory.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

ALDEYRA THERAPEUTICS INC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

01438T106

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 01438T106

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,045,764.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,045,764.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,045,764.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.7 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ALDEYRA THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 131 HARTWELL AVENUE, SUITE 320 LEXINGTON MA 02421
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 01438T106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1045764
(b)	Percent of class: 1.7 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1045764
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1045764
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of ALDEYRA THERAPEUTICS INC. No one person's interest in the common stock of ALDEYRA THERAPEUTICS INC is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	07/27/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7